Ladenburg raised the firm’s price target on TG Therapeutics to $40 from $39 and keeps a Buy rating on the shares after the company reported “impressive” Briumvi sales in Q1 and finished the quarter with $209.8M in cash, which the firm says is “more than sufficient to achieve profitability.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
- TG Therapeutics call volume above normal and directionally bullish
- TG Therapeutics contact with VA ‘unequivocal win,’ says JPMorgan
- TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
